Bone Morphogenetic Proteins
Bone Morphogenetic Proteins
复制标题
DOI：
10.1101/cshperspect.a021899
复制
发表时间：
2016-06-01
影响因子：
7.2
通讯作者：
Watabe, Tetsuro
中科院分区：
文献类型：
--
作者：
Katagiri, Takenobu;Watabe, Tetsuro
骨形态发生蛋白（BMPs）最初被鉴定为来自骨的提取物中的骨诱导组分，现在已知在包括骨、软骨、肌肉、肾和血管的各种器官的形成和维持期间的广泛过程中发挥重要作用。BMP和相关的“生长和分化因子”（GDF）是转化生长因子β（TGF-β）家族的成员，并且通过I型和II型丝氨酸-苏氨酸激酶受体及其细胞内下游效应物（包括Smad蛋白）传递它们的信号。此外，BMP信号被各种激动剂和拮抗剂精细调节。因为在信号转导的多个步骤中BMP活性的失调与多种人类疾病有关，所以BMP信号传导的激活剂和抑制剂的治疗用途将分别为治疗由BMP信号的低活化和高活化引起的人类病症提供潜在的途径。
Bone morphogenetic proteins (BMPs), originally identified as osteoinductive components in extracts derived from bone, are now known to play important roles in a wide array of processes during formation and maintenance of various organs including bone, cartilage, muscle, kidney, and blood vessels. BMPs and the related "growth and differentiation factors" (GDFs) are members of the transforming growth factor beta (TGF-beta) family, and transduce their signals through type I and type II serine-threonine kinase receptors and their intracellular downstream effectors, including Smad proteins. Furthermore, BMP signals are finely tuned by various agonists and antagonists. Because deregulation of the BMP activity at multiple steps in signal transduction is linked to a wide variety of human diseases, therapeutic use of activators and inhibitors of BMP signaling will provide potential avenues for the treatment of the human disorders that are caused by hypo-and hyperactivation of BMP signals, respectively.